First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.
Journal
Clinical and translational science
ISSN: 1752-8062
Titre abrégé: Clin Transl Sci
Pays: United States
ID NLM: 101474067
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
revised:
22
01
2024
received:
24
10
2023
accepted:
24
01
2024
medline:
18
3
2024
pubmed:
18
3
2024
entrez:
18
3
2024
Statut:
ppublish
Résumé
Relapsed/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) outcomes remain poor. A targeted cluster of differentiation (CD)33 × CD3 bispecific antibody, JNJ-67571244, was assessed to identify the maximum tolerated dose (MTD), recommended phase II dose (RP2D), safety and tolerability, and preliminary clinical activity in patients with r/rAML or r/rMDS. This first-in-human, open-label, phase I, dose-escalation/dose-expansion study included patients with r/rAML or r/rMDS who were ineligible for or had exhausted standard therapeutic options. JNJ-67571244 was administered intravenously or subcutaneously using step-up dosing until ≥1 discontinuation condition was met. Outcomes included safety/tolerability, preliminary clinical activity, and systemic pharmacokinetics and pharmacodynamics. The study was terminated after evaluating 10 dose-escalation cohorts (n = 68) and before starting dose-expansion. Overall, 11 (16.2%) patients experienced ≥1 dose-limiting toxicity; all experienced ≥1 treatment-emergent adverse event (TEAE; treatment related: 60 [88.2%]); and 64 (94.1%) experienced ≥1 TEAE of Grade ≥3 toxicity (treatment related: 28 [41.2%]). Although some patients had temporary disease burden reductions, no responses were seen. JNJ-67571244 administration increased multiple cytokines, which coincided with incidence of cytokine release syndrome, infusion-related reactions, and elevated liver function tests. A prolonged step-up strategy was tested to improve tolerability, though this approach did not prevent hepatotoxicity. T-cell activation following treatment suggested target engagement but did not correlate with clinical activity. Safely reaching the projected exposure level for JNJ-67571244 efficacy was not achieved, thus MTD and RP2D were not determined.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13742Informations de copyright
© 2024 Janssen Research and Development, LLC. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Références
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Acute Myeloid Leukemia. Version 3.2023 - April 5, 2023. National Comprehensive Cancer Network, Inc. Accessed October 20, 2023. https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf
Visser O, Trama A, Maynadie M, et al. Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer. 2012;48(17):3257-3266. doi:10.1016/j.ejca.2012.05.024
Leukemia - Acute Myeloid - AML: Subtypes. American Society of Clinical Oncology; 2022. Accessed October 20, 2023. https://www.cancer.net/cancer-types/leukemia-acute-myeloid-aml/subtypes
Myelodysplastic Syndromes -MDS: Subtypes and Classification. American Society of Clinical Oncology; 2023. Accessed October 20, 2023. https://www.cancer.net/cancer-types/myelodysplastic-syndromes-mds/subtypes-and-classification
Thol F, Heuser M. Treatment for relapsed/refractory acute myeloid leukemia. Hemasphere. 2021;5(6):e572. doi:10.1097/HS9.0000000000000572
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-232. doi:10.1016/S1470-2045(09)70003-8
Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106(8):1794-1803. doi:10.1002/cncr.21792
Jabbour E, Garcia-Manero G, Batty N, et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer. 2010;116(16):3830-3834. doi:10.1002/cncr.25247
Prebet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29(24):3322-3327. doi:10.1200/JCO.2011.35.8135
Russell-Smith TA, Gurskyte L, Muresan B, et al. Efficacy of non-intensive therapies approved for relapsed/refractory acute myeloid leukemia: a systematic literature review. Future Oncol. 2022;18(16):2029-2039. doi:10.2217/fon-2021-1355
Platzbecker U, Kubasch AS, Homer-Bouthiette C, Prebet T. Current challenges and unmet medical needs in myelodysplastic syndromes. Leukemia. 2021;35(8):2182-2198. doi:10.1038/s41375-021-01265-7
Cowan AJ, Laszlo GS, Estey EH, Walter RB. Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin. Front Biosci (Landmark ed). 2013;18(4):1311-1334. doi:10.2741/4181
Clark MC, Stein A. CD33 directed bispecific antibodies in acute myeloid leukemia. Best Pract Res Clin Haematol. 2020;33(4):101224. doi:10.1016/j.beha.2020.101224
Jilani I, Estey E, Huh Y, et al. Differences in CD33 intensity between various myeloid neoplasms. Am J Clin Pathol. 2002;118(4):560-566. doi:10.1309/1WMW-CMXX-4WN4-T55U
Kapoor S, Champion G, Basu A, Mariampillai A, Olnes MJ. Immune therapies for myelodysplastic syndromes and acute myeloid leukemia. Cancers (Basel). 2021;13(19):5026. doi:10.3390/cancers13195026
Ogata K, Nakamura K, Yokose N, et al. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood. 2002;100(12):3887-3896. doi:10.1182/blood-2002-01-0222
Chen X, Eksioglu EA, Zhou J, et al. Induction of myelodysplasia by myeloid-derived suppressor cells. J Clin Invest. 2013;123(11):4595-4611. doi:10.1172/JCI67580
Velegraki M, Stiff A, Papadaki HA, Li Z. Myeloid-derived suppressor cells: new insights into the pathogenesis and therapy of MDS. J Clin Med. 2022;11(16):4908. doi:10.3390/jcm11164908
Kittang AO, Kordasti S, Sand KE, et al. Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome. Oncoimmunology. 2016;5(2):e1062208. doi:10.1080/2162402X.2015.1062208
Eksioglu EA, Chen X, Heider KH, et al. Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the fc-engineered CD33 antibody BI 836858. Leukemia. 2017;31(10):2172-2180. doi:10.1038/leu.2017.21
Cheng P, Chen X, Dalton R, et al. Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma. Mol Ther. 2022;30(6):2315-2326. doi:10.1016/j.ymthe.2022.02.005
Mylotarg™ (Gemtuzumab Ozogamicin) for Injection Prescribing Information. Pfizer Inc.; 2021.
Rajvanshi P, Shulman HM, Sievers EL, McDonald GB. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood. 2002;99(7):2310-2314. doi:10.1182/blood.v99.7.2310
Giles FJ, Kantarjian HM, Kornblau SM, et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 2001;92(2):406-413. doi:10.1002/1097-0142(20010715)92:2<406::aid-cncr1336>3.0.co;2-u
Laszlo GS, Harrington KH, Gudgeon CJ, et al. Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia. Oncotarget. 2016;7(28):43281-43294. doi:10.18632/oncotarget.9674
Hernandez-Caselles T, Martinez-Esparza M, Perez-Oliva AB, et al. A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing. J Leukoc Biol. 2006;79(1):46-58. doi:10.1189/jlb.0205096
Menon AP, Moreno B, Meraviglia-Crivelli D, et al. Modulating T cell responses by targeting CD3. Cancers (Basel). 2023;15(4):1189. doi:10.3390/cancers15041189
Singh A, Dees S, Grewal IS. Overcoming the challenges associated with CD3+ T-cell redirection in cancer. Br J Cancer. 2021;124(6):1037-1048. doi:10.1038/s41416-020-01225-5
Blincyto® (Blinatumomab) for Injection Prescribing Information. Amgen Inc.; 2022.
Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29(18):2493-2498. doi:10.1200/JCO.2010.32.7270
Nair-Gupta P, Diem M, Reeves D, et al. A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia. Blood Adv. 2020;4(5):906-919. doi:10.1182/bloodadvances.2019001188
Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951. doi:10.1182/blood-2009-03-209262
Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-2465. doi:10.1182/blood-2012-03-420489
Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447. doi:10.1182/blood-2016-08-733196
Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419-425. doi:10.1182/blood-2005-10-4149
Bloomfield CD, Estey E, Pleyer L, et al. Time to repeal and replace response criteria for acute myeloid leukemia? Blood Rev. 2018;32(5):416-425. doi:10.1016/j.blre.2018.03.006
Kubicka E, Lum LG, Huang M, Thakur A. Bispecific antibody-targeted T-cell therapy for acute myeloid leukemia. Front Immunol. 2022;13:899468. doi:10.3389/fimmu.2022.899468
Damiani D, Tiribelli M. Present and future role of immune targets in acute myeloid leukemia. Cancers (Basel). 2022;15(1):253. doi:10.3390/cancers15010253
Tettamanti S, Pievani A, Biondi A, Dotti G, Serafini M. Catch me if you can: how AML and its niche escape immunotherapy. Leukemia. 2022;36(1):13-22. doi:10.1038/s41375-021-01350-x
Zheng L, Zhang L, Guo Y, et al. The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome. Front Immunol. 2022;13:1078421. doi:10.3389/fimmu.2022.1078421
Amgen reports first quarter 2022 financial results. PRN Newswire; 2022. Accessed October 20, 2023. https://www.prnewswire.com/news-releases/amgen-reports-first-quarter-2022-financial-results-301534573.html
Boyiadzis M, Desai P, Daskalakis N, et al. First-in-human study of JNJ-63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia. Clin Transl Sci. 2023;16(3):429-435. doi:10.1111/cts.13467